Screening for chronic kidney disease in emerging countries: Feasibility and hurdles

Nephrology Dialysis Transplantation

Volumn 24, Issue 5, 2009, Pages 1355-1358

  Perico, Norberto ^a,d   Bravo, Rodolfo Flores ^b   De Leon, Felipe Rodriguez ^c   Remuzzi, Giuseppe ^a  

^a MARIO NEGRI INST PHARMACOL RES   (Italy)

^b Hospital Juan XXIII   (Bolivia)

^c Caja de Seguro Social ^*  (Panama)

^d MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

Author keywords

Chronic kidney diseases; Developing countries; Prevention; Risk factors; Screening

Indexed keywords

CHRONIC KIDNEY DISEASE; COST CONTROL; DEVELOPING COUNTRY; HEALTH CARE COST; HEALTH PROGRAM; HUMAN; NOTE; PRIORITY JOURNAL; RISK FACTOR; SCREENING;

CHRONIC DISEASE; DEVELOPING COUNTRIES; FEASIBILITY STUDIES; HEALTH CARE COSTS; HUMANS; KIDNEY DISEASES; MASS SCREENING; RISK FACTORS;

EID: 65249133966     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfp039     Document Type: Note

References (33)

1. RemuzziG,Weening JJ. Albuminuria asearly test for vascular disease. Lancet 2005; 365: 556-557
2. Kher V. End-stage renal disease in developing countries. Kidney Int 2002; 62: 350-362
3. CodreanuI,TanaseA, SaliV et al. Preliminary results ofaprogram for detection and management of chronic kidney disease, hypertension, diabetes and cardiovascular diseaseinthe Republic of Moldova. World Congress of Nephrology, Rio de Janeiro, Brazil, 21-25 April, 2007, 419
4. Sharma SK, Karki P, Bartal N et al. A community screening for chronic kidney disease, hypertension, diabetes and their management in Dharan, Nepal. World Congress of Nephrology, Rio de Janeiro, Brazil, 21-25 April, 2007, 415
5. Zhang L, Zuo L, Xu G et al. Community-based screening for chronic kidney disease among populations older than 40 years in Beijing. Nephrol Dial Transplant 2007; 22: 1093-1099
6. Mani MK. Experience with a program for prevention of chronic renal failure in India. Kidney Int Suppl 2005; S75-S78
7. Dash SC, Agarwal SK. Incidence of chronic kidney disease in India. Nephrol Dial Transplant 2006; 21: 232-233
8. Go AS, Chertow GM, Fan D et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004; 351: 1296-1305
9. Williams B, Poulter NR, Brown MJ et al. British Hypertension Society guidelines for hypertension management 2004 (BHS-IV): summary.Br Med J 2004; 328: 634-640
10. American Diabetes Association. Standards of medical care in diabetes-2006.Diabetes Care 2006; 29(Suppl 1): S4-S42
11. Hallan SI, Dahl K, Oien CM et al. Screening strategies for chronic kidney disease in the general population: follow-up of cross sectional health survey. Br Med J 2006; 333: 1047- 1052
12. Sharma SK, Dhakal SS, Shrestha NR et al. Chronic kidney disease and risk factors for CKD at community in Nepal - a pilot study. Nephrology 2005; 10(Suppl): A147
13. Constantiner M, Sehgal AR, Humbert L et al. A dipstick protein and specific gravity algorithm accurately predicts pathological protein-uria. Am J Kidney Dis 2005; 45: 833-841
14. Atkins RC, Briganti EM, Lewis JB et al. Proteinuria reduction and progression to renal failure in patients with type 2 diabetes mellitus and overt nephropathy. Am J Kidney Dis 2005; 45: 281- 287
15. de Zeeuw D, Remuzzi G, Parving HH et al. Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL. Kidney Int 2004; 65: 2309-2320
16. Wilmer WA, Rovin BH, Hebert CJ et al. Management of glomeru-lar proteinuria: a commentary. J Am Soc Nephrol 2003; 14: 3217- 3232
17. Damsgaard EM, Froland A, Jorgensen OD et al. Microalbuminuria as predictor of increased mortality in elderly people. Br Med J 1990; 300: 297-300
18. Damsgaard EM, Froland A, Jorgensen OD et al. Eight to nine year mortality in known non-insulin dependent diabetics and controls. Kidney Int 1992; 41: 731-735
19. Grimm RH Jr, Svendsen KH, Kasiske B et al. Proteinuria is a risk factor for mortality over 10 years of follow-up. MRFIT Research Group. Multiple Risk Factor Intervention Trial. Kidney Int Suppl 1997; 63: S10-S14
20. Kannel WB, Stampfer MJ, Castelli WP et al. The prognostic significance of proteinuria: the Framingham study. Am Heart J 1984; 108: 1347-1352
21. Yuyun MF, Khaw KT, Luben R et al. A prospective study of mi-croalbuminuria and incident coronary heart disease and its prognostic significance in a British population: the EPIC-Norfolk study.Am J Epidemiol 2004; 159: 284-293
22. Yuyun MF, Khaw KT, Luben R et al. Microalbuminuria independently predicts all-cause and cardiovascular mortality in a British population: the European Prospective Investigation into Cancer in Norfolk (EPIC-Norfolk) population study. Int J Epidemiol 2004; 33: 189-198
23. Yuyun MF, Khaw KT, Luben R et al. Microalbuminuria and stroke in a British population: the European Prospective Investigation into Cancer in Norfolk (EPIC-Norfolk) population study.J Intern Med 2004; 255: 247-256
24. Harwell TS, Nelson RG, Little RR et al. Testing for microalbuminuria in 2002: barriers to implementing current guidelines. Am J Kidney Dis 2003; 42: 245-248
25. Carel RS, Silverberg DS, Kaminsky R et al. Routine urinalysis (dipstick) findings in mass screening of healthy adults. Clin Chem 1987; 33: 2106-2108
26. de Jong PE, Curhan GC. Screening, monitoring, and treatment of albuminuria: public health perspectives. J Am Soc Nephrol 2006; 17: 2120-2126
27. Parikh CR, Fischer MJ, Estacio R et al. Rapid microalbuminuria screening in type 2 diabetes mellitus: simplified approach with Micral test strips and specific gravity. Nephrol Dial Transplant 2004; 19: 1881-1885
28. Ludimu Tugirimana P, Delanghe J. Development of an affordable dye-stained microalbuminuria screening test. Nephrol Dial Transplant 2009; 24: 1485-1490
29. Bang H, Vupputuri S, Shoham DA et al. SCreening for Occult REnal Disease (SCORED): a simple prediction model for chronic kidney disease. Arch Intern Med 2007; 167: 374-381
30. Ruggenenti P, Pagano E, Tammuzzo L et al. Ramipril prolongs life and is cost effective in chronic proteinuric nephropathies. Kidney Int 2001; 59: 286-294
31. Palmer AJ, Annemans L, Roze S et al. An economic evaluation of the Irbesartan in Diabetic Nephropathy Trial (IDNT) in a UK setting.J Hum Hypertens 2004; 18: 733-738
32. Dirks JH, Robinson SW, Alderman M et al. Meeting report on the Bellagio Conference 'prevention of vascular diseases in the emerging world: an approach to global health equity'. Kidney Int 2006; 70: 1397-1402
33. International Society of Nephrology. Program for detection and management of chronic kidney disease, hypertension, diabetes, and cardiovascular disease in developing countries (KHDC). http: //www. isn-online.org/isn/education/ guidelines/isn/full/ed-051027-1.html